ArticleResearch square2026
Adaptive and sequential cancer therapies emerge from treatment schedule optimization.
Article in Research square, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Most cancer chemotherapy is delivered at the maximum tolerated dose (MTD) as often as possible, switching to a new combination of drugs upon progression. Clinical trial results have demonstrated that this sequential MTD schedule is not optimal for every patient in every situation; however, there is no systematic program for discovering what the optimal schedule actually is. We developed a simulated-annealing-based algorithm for computing personalized dosing schedules that best achieve treatment objectives. Given a mathematical model of a patient's drug response, the algorithm returns the optimal schedule for either minimizing tumor burden or maximizing progression-free survival. We tested this algorithm on a simple mathematical model of patient treatment response; we found that there are only three optimal one-drug schedules: continuous therapy and two distinct adaptive therapies. For two drugs, each schedule used in the clinic was found to be optimal for some patient parameters, and the algorithm was able to quantitatively map out the boundaries between these schedules. The optimization algorithm developed here can play a key role in upcoming personalized cancer treatment pipelines.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.